Kinase News and Research

RSS

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Scientists discover new anti-cancer and anti-metastatic molecule

A new molecule with anti-cancer and anti-metastatic properties has been discovered by teams from CNRS, CEA, the Institut Curie and Inserm, in collaboration with Australian and British researchers.

4 Sep 2012

A-kinase anchoring proteins influence levels of glucose in the body

Scientists from the United States and Sweden have discovered a new control point that could be important as a drug target for the treatment of diabetes and other metabolic diseases.

4 Sep 2012

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Glaucoma is normally caused by increased pressure of aqueous humour fluid in the eye. A defining feature of this disease is destruction of a particular type of cells in the retina called retinal ganglion cells and excavation of the optic disc region.

31 Aug 2012

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

31 Aug 2012

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.

30 Aug 2012

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Seattle Genetics, Inc. today announced the initiation of a phase Ib clinical trial evaluating SGN-75 in combination with everolimus (Afinitor) for patients with advanced metastatic renal cell carcinoma (RCC).

24 Aug 2012

Vandetanib shows efficacy in thyroid cancer

The tyrosine kinase inhibitor vandetanib could significantly extend progression-free survival in patients with locally advanced or metastatic differentiated radioiodine-refractory thyroid cancer, show results of a small phase II randomized trial.

24 Aug 2012

Spicy solution for viral infection

Curcumin, the main compound in the spice turmeric, prevents replication of mosquito-borne Rift Valley Fever virus in infected cells, report researchers.

22 Aug 2012

Acai supplementation could protect against oxidative stress and triple flies' lifespans

Bewildered by the array of antioxidant fruit juices on display in the supermarket and the promises they make? To sort out the antioxidant properties of fruits and berries, scientists at Emory University School of Medicine turned to fruit flies for help.

22 Aug 2012

FDA extends action date for Pfizer’s tofacitinib NDA review

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA).

22 Aug 2012

Study highlights Nek9 protein as decisive factor in cell division

A study by the Institute for Research in Biomedicine (IRB Barcelona) and the Center for Genomic Regulation (acronym in Catalan CRG) highlights the protein Nek9 as a decisive factor in cell division, a fundamental process for both the development of an organism and tissue maintenance.

22 Aug 2012

Study identifies mode of death of cone photoreceptor cells in animal model of RP

Research conducted at the Angiogenesis Laboratory at Massachusetts Eye and Ear Infirmary, has for the first time, identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigmentosa (RP).

21 Aug 2012

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company's investigational BCR-ABL inhibitor.

20 Aug 2012

Protein toxic to nerve cells in AD also contributes to memory loss

The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed by the activity of several enzymes, including one called BACE1. Most Alzheimer's disease patients have elevated levels of BACE1, which in turn leads to more brain-damaging β-amyloid protein.

20 Aug 2012

Pyruvate kinase M2 fuels tumor growth by influencing H3 histone protein

A metabolic protein that nourishes cancer cells also activates tumor-promoting genes by loosening part of the packaging that entwines DNA to make up chromosomes, a team led by scientists at The University of Texas MD Anderson Cancer Center reports in the Aug. 16 issue of Cell.

17 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib can induce a clinical response in the majority of patients with moderate to severe, active ulcerative colitis, a placebo-controlled trial has shown.

16 Aug 2012

Kinase News and Research

FDA approves Bosulif to treat chronic myelogenous leukemia

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Scientists discover new anti-cancer and anti-metastatic molecule

A-kinase anchoring proteins influence levels of glucose in the body

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Vandetanib shows efficacy in thyroid cancer

Spicy solution for viral infection

Acai supplementation could protect against oxidative stress and triple flies' lifespans

FDA extends action date for Pfizer’s tofacitinib NDA review

Study highlights Nek9 protein as decisive factor in cell division

Study identifies mode of death of cone photoreceptor cells in animal model of RP

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

Protein toxic to nerve cells in AD also contributes to memory loss

Pyruvate kinase M2 fuels tumor growth by influencing H3 histone protein

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Tofacitinib shows promise in active ulcerative colitis

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News